

HIV Drug Resistance Report

Patient information

Name: ****

Sex: ****

DOB/Age: ****

H&C number/SP Number:****

Lab no: **V1902918**

Sequence summary

Sequence includes HIV1 PR, codons 3-99 missing: 1-2

Sequence includes HIV1 RT, codons 1-560 missing: None

Sequence includes HIV1 IN, codons 1-279 missing: 280-288

HIV subtype: C

Drug	Generic Name	Type	Resistance Call
ATV/r	atazanavir/r	PI	Susceptible
DRV/r	darunavir/r	PI	Susceptible
FPV/r	fosamprenavir/r	PI	Susceptible
IDV/r	indinavir/r	PI	Susceptible
LPV/r	lopinavir/r	PI	Susceptible
NFV	nelfinavir	PI	Susceptible
SQV/r	saquinavir/r	PI	Susceptible
TPV/r	tipranavir/r	PI	Susceptible
ABC	abacavir	NRTI	Susceptible
AZT	zidovudine	NRTI	Susceptible
D4T	stavudine	NRTI	Susceptible
DDI	didanosine	NRTI	Susceptible
FTC	emtricitabine	NRTI	Susceptible
3TC	lamivudine	NRTI	Susceptible
TDF	tenofovir	NRTI	Susceptible
DOR	doravirine	NNRTI	Susceptible
EFV	efavirenz	NNRTI	Susceptible
ETR	etravirine	NNRTI	Susceptible
NVP	nevirapine	NNRTI	Susceptible
RPV	rilpivirine	NNRTI	Susceptible
BIC	bictegravir	INSTI	Susceptible
CAB	cabotegravir	INSTI	Susceptible
DTG	dolutegravir	INSTI	Susceptible
EVG	elvitegravir	INSTI	Susceptible
RAL	raltegravir	INSTI	Susceptible

Date of specimen collection:

Specimen type:

Date received:

Significant mutations

Protease inhibitor mutations: No mutations of this type were detected

Reverse transcriptase inhibitor mutations

- **NRTI mutations:** No mutations of this type were detected
- **NNRTI mutations:** No mutations of this type were detected

Integrase inhibitor mutations: No mutations of this type were detected

Other mutations

PR other mutations: T12P, I15V, L19I, E35D, M36I, N37D, D60E, I62V, L63V, G68E, H69K, A71T, I93L

RT other mutations: V8I, V35T, E36A, T39E, E40D, S48E, K173A, N175H, D177E, T200A, E204K, Q207D, R211G, V245Q, T286A, E291D, V292I, I293V, I329L, Q334D, G335D, R356K, G359T, T377M, K390R, A400T, E404D, V435A, A437V, L452A, L469I, D471E, T477A, Q480I, H483Q, V493A, S519N, Q524E, K530R, A554K

IN other mutations: E10D, E11D, D25E, V31I, M50T, L101I, T112V, S119P, T122I, T124N, K136Q, V201I, L234I, R269K

Significant comments

PR comments:

No comment

NRTI comments:

No comment

NNRTI comments:

No comment

INT comments:

No comment

Other comments

PR comments:

A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

RT comments:

No comment

IN comments:

No comment

Definitions for drug susceptibility

"Susceptible" indicates no evidence of reduced ARV susceptibility compared with a wild-type virus.

"Potential low-level resistance" indicates that the sequence may contain mutations indicating previous ARV exposure or may contain mutation that are associated with drug resistance only when they occur with additional mutations.

"Low-level resistance" indicates that there that the virus encoded by the submitted sequence may have reduced in vitro ARV susceptibility or that patients harboring viruses with the submitted mutations may have a suboptimal virological response to treatment with the ARV. "Intermediate resistance" indicates a high likelihood that a drug's activity will be reduced but that the drug will likely retain significant remaining antiviral activity.

High-level resistance" indicates that the predicted level of resistance is similar to those observed in viruses with the highest levels of in vitro drug resistance or that clinical data exist demonstrating that patients infected with viruses having such mutations usually have little or no virological response to treatment with the ARV. Further information is available [here](#).